Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.

Experimental cell research - 15 Aug 2014

Yasugi Masayuki, Takigawa Nagio, Ochi Nobuaki, Ohashi Kadoaki, Harada Daijiro, Ninomiya Takashi, Murakami Toshi, Honda Yoshihiro, Ichihara Eiki, Tanimoto Mitsune, Kiura Katsuyuki

Abstract excerpt

Everolimus is an orally administered mTOR inhibitor. The effect, and mechanism of action, of everolimus on lung cancers with an epidermal growth factor receptor (EGFR) mutation remain unclear. Four gefitinib-sensitive and -resistant cell lines were used in the present work. Growth inhibition was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Everolimus
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutant Proteins

Share to Neovascularization, Pathologic

Share to Quinazolines

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 24768699
DOI: 10.1016/j.yexcr.2014.04.012

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24768699-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.PMID 24768699Read ↗

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.Semantic proximity Read ↗

Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.Semantic proximity Read ↗

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.Semantic proximity Read ↗

Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.Semantic proximity Read ↗

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Semantic proximity Read ↗

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.Semantic proximity Read ↗

Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.